ABCL-853: Vispa-Cel, an Allogeneic Anti-CD19 CAR-T Therapy With a PD-1 Knockout, in Patients With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (ANTLER Phase 1 Clinical Trial)
Mohamad Cherry, Houston Holmes, James Essell, Ayad Hamdan et autres
us, au, il (code pays fourni par la source)